BACKGROUND: Advanced biliary tract carcinoma has a very poor prognosis, with chemotherapy being the mainstay of treatment. Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma. METHODS: We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma. Sorafenib was administered at a dose of 400 mg twice a day. The primary end point was the disease control rate at 12 weeks. RESULTS: A total of 46 patients were treated. In all, 26 (56%) had received chemotherapy earlier, and 36 patients completed at least 45 days of treatment. In intention-to-treat analysis, the objective response was 2% and the disease control rate at 12 weeks was 32.6%. Progression-free survival (PFS) was 2.3 months (range: 0-12 months), and the median overall survival was 4.4 months (range: 0-22 months). Performance status was significantly related to PFS: median PFS values for ECOG 0 and 1 were 5.7 and 2.1 months, respectively (P=0.0002). The most common toxicities were skin rash (35%) and fatigue (33%), requiring a dose reduction in 22% of patients. CONCLUSIONS: Sorafenib as a single agent has a low activity in cholangiocarcinoma. Patients having a good performance status have a better PFS. The toxicity profile is manageable.
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial / Bengala, C; Bertolini, Federica; Malavasi, Norma; Boni, C; Aitini, E; Dealis, Cristina; Zironi, S; Depenni, R; Fontana, Annalisa; Del Giovane, Cinzia; Luppi, G; Conte, Pierfranco. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 102(2010), pp. 68-72.
Data di pubblicazione: | 2010 |
Titolo: | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial |
Autore/i: | Bengala, C; Bertolini, Federica; Malavasi, Norma; Boni, C; Aitini, E; Dealis, Cristina; Zironi, S; Depenni, R; Fontana, Annalisa; Del Giovane, Cinzia; Luppi, G; Conte, Pierfranco |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1038/sj.bjc.6605458 |
Rivista: | |
Volume: | 102 |
Pagina iniziale: | 68 |
Pagina finale: | 72 |
Codice identificativo ISI: | WOS:000273563800010 |
Codice identificativo Scopus: | 2-s2.0-74249098818 |
Codice identificativo Pubmed: | 19935794 |
Citazione: | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial / Bengala, C; Bertolini, Federica; Malavasi, Norma; Boni, C; Aitini, E; Dealis, Cristina; Zironi, S; Depenni, R; Fontana, Annalisa; Del Giovane, Cinzia; Luppi, G; Conte, Pierfranco. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 102(2010), pp. 68-72. |
Tipologia | Articolo su rivista |
File in questo prodotto:

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris